File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Treatment of fibrosing cholestatic hepatitis with lamivudine

TitleTreatment of fibrosing cholestatic hepatitis with lamivudine
Authors
Issue Date1998
PublisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/gastro
Citation
Gastroenterology, 1998, v. 115 n. 1, p. 177-181 How to Cite?
AbstractFibrosing cholestatic hepatitis is a histological variant of hepatitis B virus infection with a high rate of mortality. We describe a patient who acquired acute hepatitis B virus infection 8 months after renal transplantation. Clinical features of rapidly progressive liver failure, indicated by prolonged prothrombin time (57 seconds) and increased bilirubin (40.4 mg/dL) and ammonia (129 μmol/L) concentrations, were accompanied by an extremely high serum HBV DNA level (2.153 x 106 pg/mL). Liver biopsy specimen showed fibrosing cholestatic hepatitis with widespread balloon degeneration of hepatocytes, focal hepatocyte loss, bile stasis, periportal fibrosis, mild lymphocytic infiltration, and strongly positive immunohistochemical staining for hepatitis B surface antigen (HBsAg) and hepatitis B core antigen. Lamivudine therapy suppressed HBV DNA to <10 pg/mL within 4 weeks, which was followed by gradual recovery of liver function from a state of hepatic precoma. Twenty-four months after the onset of hepatitis, the patient had normal prothrombin time and bilirubin, transaminase, and albumin levels. She remained HBsAg positive and hepatitis B e antigen negative. Renal allograft function was stable, with a creatinine level of 1.52 mg/dL. HBV DNA remained suppressed after 22 months of lamivudine therapy. Our experience shows that fibrosing cholestatic hepatitis and liver failure caused by HBV infection can be successfully treated with lamivudine.
Persistent Identifierhttp://hdl.handle.net/10722/76875
ISSN
2015 Impact Factor: 18.187
2015 SCImago Journal Rankings: 7.170
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChan, TMen_HK
dc.contributor.authorWu, PCen_HK
dc.contributor.authorLi, FKen_HK
dc.contributor.authorLai, CLen_HK
dc.contributor.authorCheng, IKPen_HK
dc.contributor.authorLai, KNen_HK
dc.date.accessioned2010-09-06T07:25:51Z-
dc.date.available2010-09-06T07:25:51Z-
dc.date.issued1998en_HK
dc.identifier.citationGastroenterology, 1998, v. 115 n. 1, p. 177-181en_HK
dc.identifier.issn0016-5085en_HK
dc.identifier.urihttp://hdl.handle.net/10722/76875-
dc.description.abstractFibrosing cholestatic hepatitis is a histological variant of hepatitis B virus infection with a high rate of mortality. We describe a patient who acquired acute hepatitis B virus infection 8 months after renal transplantation. Clinical features of rapidly progressive liver failure, indicated by prolonged prothrombin time (57 seconds) and increased bilirubin (40.4 mg/dL) and ammonia (129 μmol/L) concentrations, were accompanied by an extremely high serum HBV DNA level (2.153 x 106 pg/mL). Liver biopsy specimen showed fibrosing cholestatic hepatitis with widespread balloon degeneration of hepatocytes, focal hepatocyte loss, bile stasis, periportal fibrosis, mild lymphocytic infiltration, and strongly positive immunohistochemical staining for hepatitis B surface antigen (HBsAg) and hepatitis B core antigen. Lamivudine therapy suppressed HBV DNA to <10 pg/mL within 4 weeks, which was followed by gradual recovery of liver function from a state of hepatic precoma. Twenty-four months after the onset of hepatitis, the patient had normal prothrombin time and bilirubin, transaminase, and albumin levels. She remained HBsAg positive and hepatitis B e antigen negative. Renal allograft function was stable, with a creatinine level of 1.52 mg/dL. HBV DNA remained suppressed after 22 months of lamivudine therapy. Our experience shows that fibrosing cholestatic hepatitis and liver failure caused by HBV infection can be successfully treated with lamivudine.en_HK
dc.languageengen_HK
dc.publisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/gastroen_HK
dc.relation.ispartofGastroenterologyen_HK
dc.subject.meshAdulten_HK
dc.subject.meshCholestasis - drug therapyen_HK
dc.subject.meshDNA, Viral - analysisen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshFibrosisen_HK
dc.subject.meshHepatitis B - complications - drug therapyen_HK
dc.subject.meshHumansen_HK
dc.subject.meshKidney Transplantation - adverse effectsen_HK
dc.subject.meshLamivudine - therapeutic useen_HK
dc.subject.meshReverse Transcriptase Inhibitors - therapeutic useen_HK
dc.titleTreatment of fibrosing cholestatic hepatitis with lamivudineen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0016-5085&volume=115/1&spage=177&epage=181&date=1998&atitle=Treatment+of+fibrosing+cholestatic+hepatitis+with+lamivudineen_HK
dc.identifier.emailChan, TM: dtmchan@hku.hken_HK
dc.identifier.emailLai, CL: hrmelcl@hku.hken_HK
dc.identifier.emailLai, KN: knlai@hku.hken_HK
dc.identifier.authorityChan, TM=rp00394en_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.identifier.authorityLai, KN=rp00324en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/S0016-5085(98)70380-4en_HK
dc.identifier.pmid9649474-
dc.identifier.scopuseid_2-s2.0-0031782444en_HK
dc.identifier.hkuros31534en_HK
dc.identifier.volume115en_HK
dc.identifier.issue1en_HK
dc.identifier.spage177en_HK
dc.identifier.epage181en_HK
dc.identifier.isiWOS:000074434500027-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridChan, TM=7402687700en_HK
dc.identifier.scopusauthoridWu, PC=7403119323en_HK
dc.identifier.scopusauthoridLi, FK=8219093900en_HK
dc.identifier.scopusauthoridLai, CL=7403086396en_HK
dc.identifier.scopusauthoridCheng, IKP=7102537483en_HK
dc.identifier.scopusauthoridLai, KN=7402135706en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats